STAT Plus: The coronavirus pandemic could shrink some biotech startup valuations
ADOBE
The uncertainty wrought by the coronavirus pandemic could shrink valuations for some private biotechs — a trend that could have widespread ripple effects.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario